Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

E155 - A Look Back at the 2022 NEI Synapse Presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania

E155 - A Look Back at the 2022 NEI Synapse Presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania

FromNEI Podcast


E155 - A Look Back at the 2022 NEI Synapse Presentation: Bipolar Disorder Rainbow: The Spectrum of Treatments for Depression and Mania

FromNEI Podcast

ratings:
Length:
19 minutes
Released:
Aug 3, 2022
Format:
Podcast episode

Description

In this episode, we take a look back at Dr. Roger McIntyre’s presentation on the treatment spectrum for depression and mania. In this sneak peek, Dr. McIntyre focuses on the current treatments that are available for the bipolar disorder spectrum. He addresses the implications of comorbid substance abuse with respect to pharmacological treatments. He also discusses lifestyle factors that can be preventative against cognitive decline associated with mood disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.
Released:
Aug 3, 2022
Format:
Podcast episode

Titles in the series (100)

The Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health by providing imaginative medical education that focuses on the highest level of learning. Each episode offers an opportunity to learn about current issues in psychiatry from key opinion leaders in the medical field. NEI's Podcast would be of value to anyone with an interest in neuropsychiatric diseases and psychopharmacology.